Pharmaceutical

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.

Jul 15, 2025 - 06:00
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.
Read the original article

Tags:

Previous Article

Ultragenyx receives complete response letter for UX111 BLA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

Dec 1, 2023

BlueRock and bit.bio link to develop regulatory T cell-based therapies

BlueRock and bit.bio link to develop regulatory T cell-...

Aug 4, 2023

Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream

Huadong enters licence deal for MC2 Therapeutics’ Wynzo...

Sep 1, 2023